FDA Advisory Committee Against Extended Release Oxycodone Capsules

Posted by Kaela Gerald on Posted on

On June 26th, 2018 a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee reviewed New Drug Application (NDA) 022324 for extended release oxycodone capsules (Remoxy ER) by Pain Therapeutics Inc. Remoxy ER is an abuse deterrent, pain relief medication for those with severe enough
Read More

FDA Advisory Committee Opposed to Buprenorphine Sublingual Spray

Posted by Kaela Gerald on Posted on

On May 22nd, 2018 a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee discussed the new drug application (NDA) 209588 for buprenorphine sublingual spray (Buvaya), submitted by INSYS Development Company Inc. The drug is an opioid receptor indicated for the treatment of moderate-to-severe
Read More

FDA Advisory Committee Votes in Favor of WAYLIVRA (volanesorsen)

Posted by Kaela Gerald on Posted on

On May 10th, 2018 the Endocrinologic and Metabolic Drugs Advisory Committee met to review new drug application (NDA) 210645, for Akcea Therapeutics’ volanesoren. The drug is a subcutaneous injection proposed as an adjunct to diet for the treatment of familial chylomicronemia syndrome (FCS). A starting dose of 300 mg once weekly with dose adjustments based
Read More

FDA Advisory Committee Against InfaCare Pharmaceutical Corporation’s Stannsoporfin

Posted by Kaela Gerald on Posted on

On May 3rd, 2018 a joint meeting of the Gastrointestinal Drugs Advisory Committee and the Pediatric Advisory Committee was held to discuss the new drug application (NDA) 209904 for InfaCare Pharmaceutical Corporation’s stannsoporfin. Stannsoporfin is administered via intramuscular injection for the treatment of neonates, 35 weeks of gestational age and older, with indicators of hemolysis
Read More

FDA Advisory Committee Split on Indications for Achaogen’s Plazomicin

Posted by Kaela Gerald on Posted on

On May 2nd, 2018 the Antimicrobial Drugs Advisory Committee convened to review new drug application (NDA) 210303, for plazomicin, sponsored by Achaogen Inc. Plazomicin is an aminoglycoside antibacterial drug proposed for in the treatment of complicated urinary tract infections (cUTI) and blood stream infections (BSI) in patients 18 years or older, with limited or no
Read More

FDA Advisory Committee Unanimously Supports SIGA Technologies’ Tecovirimat

Posted by Kaela Gerald on Posted on

On May 1st, 2018 the Antimicrobial Drugs Advisory Committee reviewed the new drug application (NDA) 208627 for SIGA Technologies’ tecovirimat, proposed for the treatment of smallpox caused by the variola virus, in pediatrics and adults.  The drug inhibits the production of extracellular viral forms responsible for the spread of infection within the body. Although smallpox
Read More

FDA Advisory Committee on the Safety of Celecoxib, Naproxen and Ibuprofen

Posted by Kaela Gerald on Posted on

On April 24th – April 25th, 2018 a joint meeting of the Arthritis Advisory Committee and Drug Safety and Risk Management Committee convened to review supplemental new drug application (sNDA) 0209998/S-050 for Pfizer Pharmaceuticals’ COX-2 inhibitor Celecoxib (Celebrex). Celebrex is an oral tablet that can be used as an analgesic and for swelling and inflammation.
Read More

FDA Advisory Committee in Favor of 2 mg dose and Opposed to 4 mg dose of Eli Lilly’s Baricitinib

Posted by Kaela Gerald on Posted on

On April 23, 2018 a meeting of the Arthritis Advisory Committee took place to review new drug application (NDA) 207924 sponsored by Eli Lilly and Company. The new molecular entity, baricitinib, is a Janus associated kinase inhibitor proposed for the treatment of active rheumatoid arthritis in adults who have not had an appropriate response to
Read More

FDA Advisory Committee Unanimously in Favor of GW Pharmaceuticals’ Epidiolex

Posted by Kaela Gerald on Posted on

On April 19th, 2018 the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) convened to review new drug application (NDA) 210365 for GW Pharmaceuticals’ novel seizure drug, Epidiolex (cannabidiol). Cannabidiol (CBD) is an oral solution indicated for seizures associated with Lennox-Gastuat syndrome (LGS) and Dravet syndrome (DS) in patients at least 2 years old. 
Read More

Managing Relationships: Identifying and Engaging Thought Leaders in Pharma and Biotech

Posted by Kaela Gerald on Posted on

Who are Key Opinion Leaders and why they are important? Key Opinion Leaders (KOLs) are physicians and scientific experts that have an independent voice or strong impact earned from an established reputation in their field. These thought leaders are extremely useful to pharmaceutical, medical device and biotech companies, as they can play an important role
Read More